FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4323348642> ?p ?o ?g. }

• W4323348642 endingPage "721" @default.
• W4323348642 startingPage "713" @default.
• W4323348642 abstract "The Rezum System (Rezum) represents a novel, minimally invasive surgical therapy used to treat lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). We evaluated the safety and efficacy of Rezum in patients with mild, moderate, or severe LUTS.A single office, retrospective study was conducted on patients from a multiethnic population treated with Rezum between 2017 and 2019. Patients were categorized into three cohorts based on baseline International Prostate Symptom Score (IPSS) LUTS severity: mild LUTS (IPSS ≤ 7), moderate LUTS (IPSS 8-19), or severe LUTS (IPSS ≥ 20) cohorts. Outcome measures, including IPSS, quality of life (QoL), maximum urinary flow rate (Qmax), postvoid residual (PVR), BPH medication usage, and adverse events (AEs) were collected and analyzed at baseline, 1-, 3-, 6-, and/or 12-months postoperatively.A total of 238 patients were included: 33 with mild LUTS, 109 with moderate LUTS, and 96 with severe LUTS. At 1-month follow-up, the moderate and severe LUTS cohorts saw significant improvements in IPSS (moderate LUTS: -3.0 [-6.0, 1.5], p < 0.001; severe LUTS: -10.0 [-16.0, -5.0], p < 0.001) and QoL (moderate LUTS: -1.0 [-3.0, 0.0], p < 0.001; severe LUTS: -1.0 [-3.0, 0.0], p < 0.001) and improvements remained durable up to 12-months (p < 0.001). The mild LUTS cohort saw significant worsening in IPSS by 2.0 (0.0, 12.0) at 1-month (p = 0.002) but returned to baseline at 3-months (p = 0.114). However, the mild LUTS cohort experienced significant improvements in QoL by -0.5 (-3.0, 0.0) at 3-months (p = 0.035) and nocturia by 0.0 (-1.0, 0.0) at 6-months (p = 0.002), both of which remained durable to 12-months (p < 0.05). Most AEs were transient and nonserious, with gross hematuria (66.5%) being most common. There were no significant differences in QoL point reduction, Qmax improvement, PVR reduction, and AE occurrence between the cohorts at 12-months (p > 0.05). At 12-months, 80.0%, 87.5%, and 66.0% of the patients in the mild, moderate, and severe LUTS cohorts discontinued their BPH medications, respectively.Rezum provides rapid and durable relief in LUTS in patients with moderate or severe LUTS and can be offered to patients with mild LUTS who have bothersome nocturia and wish to discontinue their BPH medications." @default.
• W4323348642 created "2023-03-08" @default.
• W4323348642 creator A5002998450 @default.
• W4323348642 creator A5007014472 @default.
• W4323348642 creator A5017208541 @default.
• W4323348642 creator A5018935324 @default.
• W4323348642 creator A5029600442 @default.
• W4323348642 creator A5066973295 @default.
• W4323348642 creator A5071985221 @default.
• W4323348642 creator A5089482599 @default.
• W4323348642 date "2023-03-06" @default.
• W4323348642 modified "2023-10-02" @default.
• W4323348642 title "Rezum water vapor therapy for patients with mild, moderate, or severe lower urinary tract symptoms: A retrospective study in a multiethnic population" @default.
• W4323348642 cites W1529890067 @default.
• W4323348642 cites W1974192649 @default.
• W4323348642 cites W1983936872 @default.
• W4323348642 cites W1988025689 @default.
• W4323348642 cites W1994976193 @default.
• W4323348642 cites W2009440132 @default.
• W4323348642 cites W2009604837 @default.
• W4323348642 cites W2074757081 @default.
• W4323348642 cites W2091569598 @default.
• W4323348642 cites W2144173184 @default.
• W4323348642 cites W2286260666 @default.
• W4323348642 cites W2472933055 @default.
• W4323348642 cites W2518464930 @default.
• W4323348642 cites W2984296275 @default.
• W4323348642 cites W3023478961 @default.
• W4323348642 cites W3065317914 @default.
• W4323348642 cites W3095945060 @default.
• W4323348642 cites W3132924449 @default.
• W4323348642 cites W3145345281 @default.
• W4323348642 cites W3147127750 @default.
• W4323348642 cites W3155763064 @default.
• W4323348642 cites W3158826288 @default.
• W4323348642 cites W3174738358 @default.
• W4323348642 cites W3177829235 @default.
• W4323348642 cites W3186193323 @default.
• W4323348642 cites W3188825894 @default.
• W4323348642 cites W3190109435 @default.
• W4323348642 cites W3203808913 @default.
• W4323348642 cites W4214902387 @default.
• W4323348642 doi "https://doi.org/10.1002/pros.24508" @default.
• W4323348642 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36879380" @default.
• W4323348642 hasPublicationYear "2023" @default.
• W4323348642 type Work @default.
• W4323348642 citedByCount "0" @default.
• W4323348642 crossrefType "journal-article" @default.
• W4323348642 hasAuthorship W4323348642A5002998450 @default.
• W4323348642 hasAuthorship W4323348642A5007014472 @default.
• W4323348642 hasAuthorship W4323348642A5017208541 @default.
• W4323348642 hasAuthorship W4323348642A5018935324 @default.
• W4323348642 hasAuthorship W4323348642A5029600442 @default.
• W4323348642 hasAuthorship W4323348642A5066973295 @default.
• W4323348642 hasAuthorship W4323348642A5071985221 @default.
• W4323348642 hasAuthorship W4323348642A5089482599 @default.
• W4323348642 hasConcept C121608353 @default.
• W4323348642 hasConcept C126322002 @default.
• W4323348642 hasConcept C126894567 @default.
• W4323348642 hasConcept C159110408 @default.
• W4323348642 hasConcept C167135981 @default.
• W4323348642 hasConcept C197934379 @default.
• W4323348642 hasConcept C2776235491 @default.
• W4323348642 hasConcept C2776547966 @default.
• W4323348642 hasConcept C2779478474 @default.
• W4323348642 hasConcept C2779951463 @default.
• W4323348642 hasConcept C2908647359 @default.
• W4323348642 hasConcept C71924100 @default.
• W4323348642 hasConcept C72563966 @default.
• W4323348642 hasConcept C99454951 @default.
• W4323348642 hasConceptScore W4323348642C121608353 @default.
• W4323348642 hasConceptScore W4323348642C126322002 @default.
• W4323348642 hasConceptScore W4323348642C126894567 @default.
• W4323348642 hasConceptScore W4323348642C159110408 @default.
• W4323348642 hasConceptScore W4323348642C167135981 @default.
• W4323348642 hasConceptScore W4323348642C197934379 @default.
• W4323348642 hasConceptScore W4323348642C2776235491 @default.
• W4323348642 hasConceptScore W4323348642C2776547966 @default.
• W4323348642 hasConceptScore W4323348642C2779478474 @default.
• W4323348642 hasConceptScore W4323348642C2779951463 @default.
• W4323348642 hasConceptScore W4323348642C2908647359 @default.
• W4323348642 hasConceptScore W4323348642C71924100 @default.
• W4323348642 hasConceptScore W4323348642C72563966 @default.
• W4323348642 hasConceptScore W4323348642C99454951 @default.
• W4323348642 hasIssue "7" @default.
• W4323348642 hasLocation W43233486421 @default.
• W4323348642 hasLocation W43233486422 @default.
• W4323348642 hasOpenAccess W4323348642 @default.
• W4323348642 hasPrimaryLocation W43233486421 @default.
• W4323348642 hasRelatedWork W1978630268 @default.
• W4323348642 hasRelatedWork W2013357874 @default.
• W4323348642 hasRelatedWork W2081739484 @default.
• W4323348642 hasRelatedWork W2116616598 @default.
• W4323348642 hasRelatedWork W2142133236 @default.
• W4323348642 hasRelatedWork W2272886130 @default.
• W4323348642 hasRelatedWork W2595194668 @default.
• W4323348642 hasRelatedWork W2981331559 @default.
• W4323348642 hasRelatedWork W3165763778 @default.

• next